并发 IGH 和 EPOR 重排的 B 系急性淋巴细胞白血病--一种预后不佳的病例

Nupur Pradhan, Prabhjot Kaur, Venus Thakur, Anshu Anshu, Shailja Rathore, Praveen Sharma, Nabhajit Mallik, Man Updesh Singh Sachdeva, Mirza Saleem Amjad, Reena Das, Arihant Jain, Alka Khadwal, Sreejesh Sreedharanunni
{"title":"并发 IGH 和 EPOR 重排的 B 系急性淋巴细胞白血病--一种预后不佳的病例","authors":"Nupur Pradhan, Prabhjot Kaur, Venus Thakur, Anshu Anshu, Shailja Rathore, Praveen Sharma, Nabhajit Mallik, Man Updesh Singh Sachdeva, Mirza Saleem Amjad, Reena Das, Arihant Jain, Alka Khadwal, Sreejesh Sreedharanunni","doi":"10.1007/s12288-024-01818-7","DOIUrl":null,"url":null,"abstract":"<p>The <i>EPOR</i> rearrangement, an uncommon cytogenetic abnormality linked to <i>BCR::ABL1</i>-like B-ALL, is often underdiagnosed due to the absence of a robust testing strategy, especially in resource-constrained settings. We report six cases of B-ALL with concurrent <i>IGH</i> and <i>EPOR</i> rearrangement from India, representing 1.3% of the tested cases, and reviewed the existing literature. The age ranged from 13 to 37 years (median 17 years), with a 2:1 male dominance. Leukocytosis was observed in 67% of patients (median total leukocyte count-105.9 × 10^9/L), and CD20 expression was seen in 67%. One patient experienced induction failure, while three relapsed within a year of diagnosis and treatment. All six patients died within 6 to 21 months of follow-up. These findings align with previous reports of treatment resistance, frequent relapses, and the need for novel therapeutic agents like <i>JAK</i> inhibitors and CART therapy. In summary, these six B-ALL cases with <i>IGH</i> and <i>EPOR</i> rearrangements highlight the diagnostic challenges and poor outcomes associated with this condition.</p>","PeriodicalId":13314,"journal":{"name":"Indian Journal of Hematology and Blood Transfusion","volume":"1 1","pages":""},"PeriodicalIF":0.9000,"publicationDate":"2024-07-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"B Lineage Acute Lymphoblastic Leukemia with concurrent IGH and EPOR rearrangements – An Entity with Dismal Outcome\",\"authors\":\"Nupur Pradhan, Prabhjot Kaur, Venus Thakur, Anshu Anshu, Shailja Rathore, Praveen Sharma, Nabhajit Mallik, Man Updesh Singh Sachdeva, Mirza Saleem Amjad, Reena Das, Arihant Jain, Alka Khadwal, Sreejesh Sreedharanunni\",\"doi\":\"10.1007/s12288-024-01818-7\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>The <i>EPOR</i> rearrangement, an uncommon cytogenetic abnormality linked to <i>BCR::ABL1</i>-like B-ALL, is often underdiagnosed due to the absence of a robust testing strategy, especially in resource-constrained settings. We report six cases of B-ALL with concurrent <i>IGH</i> and <i>EPOR</i> rearrangement from India, representing 1.3% of the tested cases, and reviewed the existing literature. The age ranged from 13 to 37 years (median 17 years), with a 2:1 male dominance. Leukocytosis was observed in 67% of patients (median total leukocyte count-105.9 × 10^9/L), and CD20 expression was seen in 67%. One patient experienced induction failure, while three relapsed within a year of diagnosis and treatment. All six patients died within 6 to 21 months of follow-up. These findings align with previous reports of treatment resistance, frequent relapses, and the need for novel therapeutic agents like <i>JAK</i> inhibitors and CART therapy. In summary, these six B-ALL cases with <i>IGH</i> and <i>EPOR</i> rearrangements highlight the diagnostic challenges and poor outcomes associated with this condition.</p>\",\"PeriodicalId\":13314,\"journal\":{\"name\":\"Indian Journal of Hematology and Blood Transfusion\",\"volume\":\"1 1\",\"pages\":\"\"},\"PeriodicalIF\":0.9000,\"publicationDate\":\"2024-07-10\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Indian Journal of Hematology and Blood Transfusion\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1007/s12288-024-01818-7\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Indian Journal of Hematology and Blood Transfusion","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s12288-024-01818-7","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

EPOR重排是与BCR::ABL1样B-ALL相关的一种不常见的细胞遗传学异常,由于缺乏强有力的检测策略,EPOR往往诊断不足,尤其是在资源有限的环境中。我们报告了来自印度的六例同时伴有IGH和EPOR重排的B-ALL病例,占检测病例的1.3%,并回顾了现有文献。患者年龄从13岁到37岁不等(中位数为17岁),男性占2:1。67%的患者出现白细胞增多(白细胞总数中位数为 105.9 × 10^9/L),67%的患者出现 CD20 表达。一名患者诱导失败,三名患者在诊断和治疗后一年内复发。所有六名患者均在随访的 6 至 21 个月内死亡。这些发现与之前关于耐药性、频繁复发以及需要新型治疗药物(如JAK抑制剂和CART疗法)的报道一致。总之,这六例伴有IGH和EPOR重排的B-ALL病例凸显了与这种疾病相关的诊断难题和不良预后。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

摘要图片

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
B Lineage Acute Lymphoblastic Leukemia with concurrent IGH and EPOR rearrangements – An Entity with Dismal Outcome

The EPOR rearrangement, an uncommon cytogenetic abnormality linked to BCR::ABL1-like B-ALL, is often underdiagnosed due to the absence of a robust testing strategy, especially in resource-constrained settings. We report six cases of B-ALL with concurrent IGH and EPOR rearrangement from India, representing 1.3% of the tested cases, and reviewed the existing literature. The age ranged from 13 to 37 years (median 17 years), with a 2:1 male dominance. Leukocytosis was observed in 67% of patients (median total leukocyte count-105.9 × 10^9/L), and CD20 expression was seen in 67%. One patient experienced induction failure, while three relapsed within a year of diagnosis and treatment. All six patients died within 6 to 21 months of follow-up. These findings align with previous reports of treatment resistance, frequent relapses, and the need for novel therapeutic agents like JAK inhibitors and CART therapy. In summary, these six B-ALL cases with IGH and EPOR rearrangements highlight the diagnostic challenges and poor outcomes associated with this condition.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
82
期刊介绍: Indian Journal of Hematology and Blood Transfusion is a medium for propagating and exchanging ideas within the medical community. It publishes peer-reviewed articles on a variety of aspects of clinical hematology, laboratory hematology and hemato-oncology. The journal exists to encourage scientific investigation in the study of blood in health and in disease; to promote and foster the exchange and diffusion of knowledge relating to blood and blood-forming tissues; and to provide a forum for discussion of hematological subjects on a national scale. The Journal is the official publication of The Indian Society of Hematology & Blood Transfusion.
期刊最新文献
Can Health Literacy Effectively Enhance Blood Donation Rates? Assessment of Cardiac, Hepatic and Pancreatic Iron Overload in Transfusion Dependent Thalassemia Patients Using T2* Magnetic Resonance Imaging Frameshift Mutation in the EPB41 Gene with Hereditary Elliptocytosis Through the Eyes of the Recipient: Navigating Transfusion Services Amidst COVID-19 in Multi-Transfused Thalassaemic Patients An In-Depth Analysis of Variable Dynamics Influencing Bone Mineral Density in Transfusion-Dependent Thalassemia Patients
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1